{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T08:28:32Z","timestamp":1773995312045,"version":"3.50.1"},"reference-count":32,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011619","name":"Society for Immunotherapy of Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.bbmt.2020.06.012","type":"journal-article","created":{"date-parts":[[2020,6,24]],"date-time":"2020-06-24T12:08:05Z","timestamp":1593000485000},"page":"1679-1688","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["Non-Myeloablative Allogeneic Transplantation with Post-Transplant Cyclophosphamide after Immune Checkpoint Inhibition for Classic Hodgkin Lymphoma: A Retrospective Cohort Study"],"prefix":"10.1016","volume":"26","author":[{"given":"Suman","family":"Paul","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianna","family":"Zahurak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leo","family":"Luznik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard F.","family":"Ambinder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ephraim J.","family":"Fuchs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Bola\u00f1os-Meade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nina","family":"Wagner-Johnston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lode J.","family":"Swinnen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Schoch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ravi","family":"Varadhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard J.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas E.","family":"Gladstone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.bbmt.2020.06.012_bib0001","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","article-title":"Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial","volume":"17","author":"Younes","year":"2016","journal-title":"Lancet Oncol"},{"issue":"19","key":"10.1016\/j.bbmt.2020.06.012_bib0002","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","article-title":"Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic Hodgkin lymphoma","volume":"35","author":"Chen","year":"2017","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.bbmt.2020.06.012_bib0003","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/bmt.2016.348","article-title":"Haploidentical transplantation with post-infusion cyclophosphamide in advanced Hodgkin lymphoma","volume":"52","author":"Castagna","year":"2017","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.bbmt.2020.06.012_bib0004","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.bbmt.2017.11.030","volume":"24","author":"Mariotti","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"30","key":"10.1016\/j.bbmt.2020.06.012_bib0005","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1200\/JCO.2017.72.6869","volume":"35","author":"Martinez","year":"2017","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.bbmt.2020.06.012_bib0006","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1182\/blood-2016-09-738385","article-title":"Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed\/refractory lymphoma","volume":"129","author":"Merryman","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bbmt.2020.06.012_bib0007","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.bbmt.2018.08.028","article-title":"Significant risk of graft-versus-host disease with exposure to checkpoint inhibitors before and after allogeneic transplantation","volume":"25","author":"Ijaz","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"10.1016\/j.bbmt.2020.06.012_bib0008","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1634\/theoncologist.2017-0004","article-title":"FDA approval summary: nivolumab for the treatment of relapsed or progressive classical Hodgkin lymphoma","volume":"22","author":"Kasamon","year":"2017","journal-title":"Oncologist"},{"issue":"10","key":"10.1016\/j.bbmt.2020.06.012_bib0009","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1002\/cncr.32796","article-title":"Posttransplantation cyclophosphamide improves transplantation outcomes in patients with AML\/MDS who are treated with checkpoint inhibitors","volume":"126","author":"Oran","year":"2020","journal-title":"Cancer"},{"issue":"17","key":"10.1016\/j.bbmt.2020.06.012_bib0010","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1182\/bloodadvances.2018019208","article-title":"Immune checkpoint inhibitors as a bridge to allogeneic transplantation with posttransplant cyclophosphamide","volume":"2","author":"Schoch","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.bbmt.2020.06.012_bib0011","unstructured":"US Food and Drug Administration. Nivolumab (Opdivo) for Hodgkin lymphoma. 2016. Available at: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/nivolumab-opdivo-hodgkin-lymphoma. Accessed January 16, 2020."},{"key":"10.1016\/j.bbmt.2020.06.012_bib0012","unstructured":"US Food and Drug Administration. Pembrolizumab (KEYTRUDA) for classical Hodgkin lymphoma. 2017. Available at: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/pembrolizumab-keytruda-classical-hodgkin-lymphoma. Accessed January 16, 2020."},{"issue":"7","key":"10.1016\/j.bbmt.2020.06.012_bib0013","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1053\/bbmt.2002.v8.pm12171484","article-title":"Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide","volume":"8","author":"O'Donnell","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"issue":"16","key":"10.1016\/j.bbmt.2020.06.012_bib0014","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1182\/blood-2009-11-251595","article-title":"High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease","volume":"115","author":"Luznik","year":"2010","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.bbmt.2020.06.012_bib0015","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.bbmt.2018.01.011","article-title":"Shortened-duration tacrolimus after nonmyeloablative, HLA-haploidentical bone marrow transplantation","volume":"24","author":"Kasamon","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"10.1016\/j.bbmt.2020.06.012_bib0016","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","article-title":"HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide","volume":"14","author":"Luznik","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.bbmt.2020.06.012_bib0017","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.bbmt.2019.11.008","article-title":"Allogeneic haploidentical blood or marrow transplantation with post-transplantation cyclophosphamide in chronic lymphocytic leukemia","volume":"26","author":"Paul","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"10.1016\/j.bbmt.2020.06.012_bib0018","first-page":"825","article-title":"1994 Consensus conference on acute GVHD grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.bbmt.2020.06.012_bib0019","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 Diagnosis and Staging Working Group report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"446","key":"10.1016\/j.bbmt.2020.06.012_bib0020","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine JP,","year":"1999","journal-title":"J Am Stat Assoc"},{"issue":"24","key":"10.1016\/j.bbmt.2020.06.012_bib0021","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1001\/jama.2016.17700","article-title":"Negative control outcomes: a tool to detect bias in randomized trials","volume":"316","author":"Arnold","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.bbmt.2020.06.012_bib0022","unstructured":"US Food and Drug Administration. Highlights of prescribing information Adcetris\u00ae (brentuximab vedotin) for injection, for intravenous use. FDA; US Food and Drug Administration. City: Silver Spring, MD. 10\/15\/2019. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/125388s100lbl.pdf. Access date: 7\/13\/2020."},{"key":"10.1016\/j.bbmt.2020.06.012_bib0023","unstructured":"US Food and Drug Administration. Highlights of prescribing information Keytruda\u00ae (pembrolizumab) injection, for intravenous use. Initial U.S. approval: 2014. FDA; US Food and Drug Administration. City: Silver Spring, MD. 01\/09\/2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/125514s084lbl.pdf. Access date: 7\/13\/2020."},{"key":"10.1016\/j.bbmt.2020.06.012_bib0024","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1200\/EDBK_238799","article-title":"Relapsed and refractory classical Hodgkin lymphoma: keeping pace with novel agents and new options for salvage therapy","volume":"39","author":"Moskowitz","year":"2019","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"15\/supplement","key":"10.1016\/j.bbmt.2020.06.012_bib0025","article-title":"KEYNOTE-204: Randomized, open-label, phase III study of pembrolizumab (pembro) versus brentuximab vedotin (BV) in relapsed or refractory classic Hodgkin lymphoma (R\/R cHL)","volume":"38","author":"Kuruvilla","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2020.06.012_bib0026","series-title":"Blood (2019) 134 (Supplement_1): 239. doi.org\/10.1182\/blood-2019-123162","article-title":"PET-Adapted Nivolumab or Nivolumab Plus ICE As First Salvage Therapy in Relapsed or Refractory Hodgkin Lymphoma","author":"Herrera","year":"2019"},{"issue":"11","key":"10.1016\/j.bbmt.2020.06.012_bib0027","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1182\/blood-2017-10-811224","article-title":"Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma","volume":"131","author":"Herrera","year":"2018","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.bbmt.2020.06.012_bib0028","doi-asserted-by":"crossref","first-page":"4081","DOI":"10.1182\/bloodadvances.2019000134","article-title":"PTCy ameliorates GVHD by restoring regulatory and effector T-cell homeostasis in recipients with PD-1 blockade","volume":"3","author":"Ikegawa","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.bbmt.2020.06.012_bib0029","series-title":"Blood (2019) 134 (Supplement_1): 775. doi.org\/10.1182\/blood-2019-125039","article-title":"Safety and efficacy of allogeneic hematopoietic stem cell transplant after programmed cell death 1 (PD-1)\/programmed cell death ligand 1 (PD-L1) blockade for classical Hodgkin lymphoma: analysis of a large international cohort","author":"Merryman","year":"2019"},{"issue":"7","key":"10.1016\/j.bbmt.2020.06.012_bib0030","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1182\/bloodadvances.2019001336","article-title":"Checkpoint inhibition before haploidentical transplantation with posttransplant cyclophosphamide in Hodgkin lymphoma","volume":"4","author":"De Philippis","year":"2020","journal-title":"Blood Adv"},{"issue":"1)(suppl 1","key":"10.1016\/j.bbmt.2020.06.012_bib0031","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.bbmt.2007.10.025","article-title":"Graft failure after allogeneic hematopoietic cell transplantation","volume":"14","author":"Mattsson","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"10.1016\/j.bbmt.2020.06.012_bib0032","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1097\/01.TP.0000064211.23536.AD","article-title":"Nonmyeloablative haploidentical stem-cell transplantation using anti-CD2 monoclonal antibody (MEDI-507)-based conditioning for refractory hematologic malignancies","volume":"75","author":"Spitzer","year":"2003","journal-title":"Transplantation"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879120303670?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879120303670?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:12:39Z","timestamp":1761059559000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879120303670"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":32,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S1083879120303670"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2020.06.012","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Non-Myeloablative Allogeneic Transplantation with Post-Transplant Cyclophosphamide after Immune Checkpoint Inhibition for Classic Hodgkin Lymphoma: A Retrospective Cohort Study","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2020.06.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}